Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Sclerotherapy Workup

  • Author: Samer Alaiti, MD, RVT, RPVI, FACP; Chief Editor: Jorge I de la Torre, MD, FACS  more...
 
Updated: Mar 11, 2015
 

Imaging Studies

Duplex ultrasonography is the diagnostic method of choice for diagnosing venous disease. A thorough workup is warranted in the presence of symptoms such as aching, cramps, fatigue and swelling of the lower limbs, along with a positive family history of varicose veins; in the presence of varicose veins, and in patients who have a cutaneous manifestation of an underlying venous disease (stasis dermatitis, stasis ulcers, lipodermatosclerosis, atrophie blanche).

Duplex ultrasonography is the most frequently used investigation for the diagnosis and management of chronic venous disease (both deep and superficial) in the lower extremities. It should demonstrate both the anatomical patterns of veins and abnormalities of venous blood flow in the limbs (functional impairment). Duplex ultrasonography has largely replaced handheld nonimaging (continuous wave [CW]) audible Doppler instruments to assess venous disease and confirm clinical impressions.[7] For more information, see Radiology article Deep Venous Thrombosis, Lower Extremity.

Next

Other Tests

Other available functional tests for venous disease include photoplethysmography and air plethysmography.

Previous
 
 
Contributor Information and Disclosures
Author

Samer Alaiti, MD, RVT, RPVI, FACP Clinical Associate Professor, Department of Dermatology, Keck School of Medicine of the University of Southern California; Medical Director, Miracle Mile Medical Center for Dermatology and Cosmetic Surgery, Inc

Samer Alaiti, MD, RVT, RPVI, FACP is a member of the following medical societies: American Academy of Dermatology, American College of Phlebology, American College of Physicians-American Society of Internal Medicine, American Society for Dermatologic Surgery, American Society for Laser Medicine and Surgery

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Mark E Krugman, MD Assistant Professor of Plastic Surgery, Clinical Professor of Otolaryngology-Head and Neck Surgery, University of California at Irvine School of Medicine

Mark E Krugman, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Surgeons, American Society of Plastic Surgeons, American Academy of Facial Plastic and Reconstructive Surgery, American Society for Aesthetic Plastic Surgery, American Society for Laser Medicine and Surgery

Disclosure: Nothing to disclose.

Chief Editor

Jorge I de la Torre, MD, FACS Professor of Surgery and Physical Medicine and Rehabilitation, Chief, Division of Plastic Surgery, Residency Program Director, University of Alabama at Birmingham School of Medicine; Director, Center for Advanced Surgical Aesthetics

Jorge I de la Torre, MD, FACS is a member of the following medical societies: American Burn Association, American College of Surgeons, American Medical Association, American Society for Laser Medicine and Surgery, American Society of Maxillofacial Surgeons, American Society of Plastic Surgeons, American Society for Reconstructive Microsurgery, Association for Academic Surgery, Medical Association of the State of Alabama

Disclosure: Nothing to disclose.

Additional Contributors

Shahin Javaheri, MD Chief, Department of Plastic Surgery, Martinez Veterans Affairs Outpatient Clinic; Consulting Staff, Advanced Aesthetic Plastic & Reconstructive Surgery

Shahin Javaheri, MD is a member of the following medical societies: American Academy of Otolaryngology-Head and Neck Surgery, American Society of Plastic Surgeons

Disclosure: Nothing to disclose.

Acknowledgements

The authors and editors of Medscape Drugs & Diseases gratefully acknowledge the contributions of previous authors Laurence Z Rosenberg, MD; Jorge I de la Torre, MD, FACS; Gary D Monheit, MD; and John D Kayal, MD; to the development and writing of this article.

References
  1. Kahle B, Leng K. Efficacy of sclerotherapy in varicose veins-- prospective, blinded, placebo-controlled study. Dermatol Surg. 2004 May. 30(5):723-8; discussion 728. [Medline].

  2. Tisi PV, Beverley C, Rees A. Injection sclerotherapy for varicose veins. Cochrane Database of Systematic Reviews. 2006. Issue 4, Art. No.: CD001732. DOI: 10.1002/14651858.CD001732.pub2.:1372.

  3. Engel A, Johnson ML, Haynes SG. Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971-1974. Arch Dermatol. 1988 Jan. 124(1):72-9. [Medline].

  4. [Guideline] National Clinical Guideline Centre (UK). Varicose Veins in the Legs: The Diagnosis and Management of Varicose Veins. 2013 Jul. [Medline]. [Full Text].

  5. Parsons ME. Sclerotherapy basics. Dermatol Clin. 2004 Oct. 22(4):501-8, xi. [Medline].

  6. Sadick NS. Predisposing factors of varicose and telangiectatic leg veins. J Dermatol Surg Oncol. 1992 Oct. 18(10):883-6. [Medline].

  7. Raymond-Martimbeau P. The role of duplex ultrasound in the sclerotherapy of varicose veins. Phlebology Digest. 1994. 1:4-10.

  8. Feied CF. Sclerosing Solutions. Fronek H, ed. The Fundamentals of Phlebology, Venous Disease for Clinicians. 2nd. American College of Phlebology; 2007. 23.

  9. Kern P, Ramelet AA, Wutschert R, Bounameaux H, Hayoz D. Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatol Surg. 2004 Mar. 30(3):367-72; discussion 372. [Medline].

  10. Breu FX, Guggenbichler S. European consensus meeting on foam sclerotherapy. Dermatol Surg. 2004. 30:709-717.

  11. Weiss RA, Sadick NS, Goldman MP, Weiss MA. Post-sclerotherapy compression: controlled comparative study of duration of compression and its effects on clinical outcome. Dermatol Surg. 1999 Feb. 25(2):105-8. [Medline].

  12. Zimmet SE. The prevention of cutaneous necrosis following extravasation of hypertonic saline and sodium tetradecyl sulfate. J Dermatol Surg Oncol. 1993 Jul. 19(7):641-6. [Medline].

  13. Kern P, Ramelet AA, Wutschert R, Hayoz D. Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. J Vasc Surg. 2007 Jun. 45(6):1212-6. [Medline].

  14. Goldman MP. Complications and Adverse Sequelae of Sclerotherapy. Bergan JJ, ed. The Vein Book. Elsevier Academic Press; 2007. 139.

  15. Guex JJ, Allaert FA, Gillet JL, Chleir F. Immediate and midterm complications of sclerotherapy: report of a prospective multicenter registry of 12,173 sclerotherapy sessions. Dermatol Surg. 2005 Feb. 31(2):123-8; discussion 128. [Medline].

Previous
Next
 
Telangiectasias.
Reticular veins.
Venulectasias.
Venulectasias after sclerotherapy treatment.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.